Wednesday, January 08, 2014 7:43:48 PM
source: wikipedia
There is a lengthy/expensive Development and Approval process for drugs.
If a toxic drug is meant to treat symptoms or conditions like pain, boredom and stress how does the drug regulatory body or the DOJ determines which drug gets to bypass the development and approval process and which will not? In essence, just how does the regulatory body picks winners and losers or is it the DOJ who has the final word? Rule of men or rule of law?
NanoViricides, Inc. is moving FluCide through the lengthy/expensive Development and Approval process as required by law. Above all, FluCide is low-toxicity and it goes to destroy the root cause of the problem, a virus, in a matter of hours. We also know that FluCide has been effective in 6000 animals (latest figure). Why can 't we get at least a limited license to try our therapeutic drug in the market, at the end of GLP BASi "tox and safety studies"? Just think the money and time that could be saved, the lives that could be saved if we were able to "bypass" the regulatory body, just like toxic Marijuana, straight to market. The money saved could be employed to quickly advance DengueCide, HIVCide and expand the cGMP plant capacity.
Recent NNVC News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/27/2024 08:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
FEATURED CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • Oct 8, 2024 8:00 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM